M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

Table 1 Patients’ characteristics at baseline and sustained virologic response 12

Measures	Baseline	SVR12	P value
Age (yr)	52.3 ± 10.7
Gender	40 (50%) males and 40 (50%) females
BMI	28 ± 5.4
HCV RNA (log copies/mL)	6.0 ± 0.7	Non-detectable	0.000b
Platelets count (× 103/mL)	220.3 ± 65.3	245.3 ± 77.8	0.005b
ALT (IU/L)	40.5 (29-54)	32 (26-38)	< 0.001b
AST (IU/L)	39 (29-51)	30 (24-37)	< 0.001b
ALP (IU/L)	138.5 (95.5-196)	107 (86-141)	< 0.001b
Albumin (g/dL)	3.8 ± 0.3	4.2 ± 0.4	< 0.001b
Total bilirubin (mg/dL)	0.7 (0.5-0.8)	0.7 (0.5-0.95)	0.8
Creatinine (mg/dL)	0.86 ± 0.19	0.75 ± 0.23	0.002b
INR	1.06 ± 0.09	1.08 ± 0.15	0.222
AFP (ng/mL)	4.5 ± 2.1	3.7 ± 1.9	0.128
LSM (kPa)	11.4 ± 4.5	9.5 ± 3.3	0.002b
FIB-4 score	1.8 ± 0.5	1.3 ± 0.7	< 0.001b
PAPAS index	2.2 ± 0.5	2.1 ± 0.3	0.010a
Serum M2BPGi (ng/mL)	9 ± 3.8	6.7 ± 2.3	< 0.001b

The values are expressed as mean ± SD or median (IQR).

^aP < 0.05.

^bP < 0.01. SVR: Sustained virologic response; WBC: White blood cell count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; AFP: Alpha fetoprotein; LSM; Liver stiffness measurement; M2BPGi: Mac-2 binding protein glycosylation isomer.